JPRN-UMIN000013928已完成2 期
Phase II study of Eribulin every other week maintenance therapy, after induction therapy of Eribulin on day1 and 8 for 3 cycles, in patients with hormone receptor positive and HER2-negative advanced recurrent breast cancer. - JACCRO BC-03 study
onprofit Organization Japan Clinical Cancer Research Organization0 个研究点目标入组 60 人开始时间: 2014年5月13日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •(1) Active multiple malignancy (Synchronous multiple malignancy or metachronous multiple malignancy within 5 years disease free interval). (2) Patients with severe infection. (3) Patients with following severe concomitant disease; 1) Uncontrolled cardiovascular disease including ischemic cardiac disease and arrhythmia. 2) Myocardial infarction within the previous 6 months. 3) Hepatic cirrhosis. 4) Active hepatitis. 5) Interstitial lung disease or pulmonary fibrosis. 6) Hemorrhagic tendency. (4) Patients treated with steroid for brain metastasis or available carcinomatous meningitis. (5) Patients with prior history of severe hypersensitivity. (6) Prior eribulin treatment for breast cancer. (7) Patients with clinically significant psychiatric disease assessed as difficult for this study inclusion. (8) Women who are unwilling to avoid pregnancy. Women who are pregnant or breastfeeding. Women with a positive pregnancy test. (9) Any other cases who are regarded as inadequate for study enrollment by investigators
研究者
相似试验
已完成
不适用
Study to evaluate the bi-weekly schedule of eribulin for patients with advanced or reccurent breast cancerJPRN-UMIN000009084Yokohama City University Medical Center20
已完成
1 期
CLINICAL TRIAL II OF IROFULVEN EVERY TWO WEEKS IN PATIENTS WITH IRRESECABLE HEPATOCELLULAR CARCINOMAPER-015-03MGI PHARMA, INC.,
进行中（未招募）
1 期
A clinical trial to look at the safety and possible benefit, of alternating the drug eribulin with an Aromatase Inhibitor, in patients with pre-treated oestrogen receptor positive (ER+ve) breast cancer.Patients with locally advanced or metastatic oestrogen receptor positive (ER+ve) breast cancer who have received at least one hormonal therapy and at least one chemotherapy in the metastatic setting.MedDRA version: 18.0 Level: PT Classification code 10057654 Term: Breast cancer female System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0 Level: LLT Classification code 10027475 Term: Metastatic breast cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0 Level: PT Classification code 10055113 Term: Breast cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0 Level: LLT Classification code 10070575 Term: Estrogen receptor positive breast cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-004112-11-GBImperial College London12
进行中（未招募）
不适用
Phase II Clinical Trial ok weekly administration of oxaliplatin plus capecitabine and radioteraphy followed by surgery in patients with resectable locally advanced rectal cancerPre-surgical Locally advanced rectal cancer treatment.EUCTR2004-004475-12-ESGrupo de Tratamiento de los Tumores Digestivos
招募中
2 期
A phase II study of biweekly Docetaxel + Nedaplatin in advanced esophageal cancer in patients previously treated with FP and anti-PD-1 antibodiesEsophageal cancerJPRN-jRCTs061210089agano Hiroaki18